Should the Medicare $2,000 per year cap on out-of-pocket costs for prescription drugs be extended to commercial insurance?
One of the most important provisions of the Inflation Reduction Act caps the out-of-pocket prescription drug costs of Medicare Beneficiaries. A $3,250 cap went into effect this year and will be lowered to $2,000 next year. But the limit only applies to those with Part D Medicare coverage, the part of Medicare that covers prescription drugs. President Joe Biden proposed extending the cap to health insurance sold on the commercial market in his State of the Union speech last week. Proponents of such limits say they make high-priced medications affordable, improving access to drugs that can reduce illness and lengthen lives. Detractors say limits will make premiums more expensive and also have long-term negative effects on the development of drugs.
Should the Medicare $2,000 per year cap on out-of-pocket costs for prescription drugs be extended to commercial insurance?
Please pick the statement that most closely resembles your view
Should the Medicare $2,000 per-year cap on out-of-pocket costs for prescription drugs be extended to commercial insurance?
We want to know what you’re thinking! Every Monday morning the editors of Managed Healthcare Executive are posing a question to our readers about a timely issue in U.S. healthcare. Answers will be published every Friday.
Two Opdivo Updates from Bristol Myers Squibb
May 14th 2024First approved by the U.S. Food and Drug Administration (FDA) in 2014, Opdivo has multiple indications across various types of cancer, including NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma.
Read More
This data is based off of a study conducted by a group of researchers led by Niklas Frahm from the German Multiple Sclerosis Registry to compare the characteristics of patients with MS who switched from their first disease-modifying therapies (DMT) with those of patients who continued taking their first DMT.
Read More